NervGen Pharma Corp.
NGEN.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.57M | -1.20M | -19.30M | -3.02M | -6.58M |
| Total Depreciation and Amortization | 9.80K | 10.00K | 10.00K | 10.10K | 10.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.10M | -3.38M | 14.84M | -636.80K | 3.35M |
| Change in Net Operating Assets | -574.60K | -1.32M | -138.20K | -217.00K | 573.50K |
| Cash from Operations | -4.04M | -5.90M | -4.59M | -3.86M | -2.65M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 6.00K | 18.10K | 18.30K | 18.20K |
| Cash from Investing | 0.00 | 6.00K | 18.10K | 18.30K | 18.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | -8.40K | -25.20K | -25.20K | -25.20K |
| Issuance of Common Stock | 83.95M | 2.84M | 16.97M | 1.10M | 4.92M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.80M | -50.50K | -207.40K | -80.60K | -144.60K |
| Cash from Financing | 55.02M | 2.00M | 12.01M | 722.60K | 3.43M |
| Foreign Exchange rate Adjustments | -1.54M | -71.20K | 240.90K | -9.40K | 65.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.45M | -3.96M | 7.68M | -3.13M | 869.70K |